Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Jul;37(7):1414–1416. doi: 10.1128/aac.37.7.1414

Pharmacokinetics of cefepime in cystic fibrosis patients.

C E Huls 1, R A Prince 1, D K Seilheimer 1, J A Bosso 1
PMCID: PMC187985  PMID: 8363368

Abstract

The purposes of this study were to determine and compare the single- and multiple-dose pharmacokinetics of cefepime in patients with and without cystic fibrosis. Twelve patients with cystic fibrosis hospitalized for treatment of acute pulmonary exacerbations were studied. In addition, pharmacokinetic data for seven of the patients with cystic fibrosis were compared with those for seven age-matched control patients. The cefepime dose was 50 mg/kg of body weight (maximum, 2 g) administered as a 30-min intravenous infusion every 8 h for a minimum of 8 days. Serial plasma and urine samples, obtained after the first and last doses, were analyzed for cefepime content by a validated high-pressure liquid chromatographic assay. By standard noncompartmental analysis, the pharmacokinetic parameters ascertained were area under the concentration in plasma-time curve, elimination half-life, total body clearance, renal clearance, and volume of distribution at steady state. In addition, the maximum concentration in plasma was recorded. Mean (+/- standard deviation) results of the first dose analysis in patients with cystic fibrosis were as follows: maximum concentration in plasma, 142.6 (+/- 26.07) micrograms/ml; area under the concentration in plasma-time curve, 265.3 (+/- 114.31) micrograms.h/ml; elimination half-life, 1.8 (+/- 0.53) h; total body clearance, 127.2 (+/- 50.94) ml/min; renal clearance, 91.1 (+/- 38.86) ml/min/kg; volume of distribution at steady state, 14.1 (+/- 4.31) liters. Analysis for the last dose in patients with cystic fibrosis did not vary appreciably from these values, nor did those from the controls. Thus, it appears that the first-dose pharmacokinetics of cefepime are predictive of those at steady state. In order to consistently exceed the MIC for Pseudomonas aeruginosa for the entire dosing interval in patients with cystic fibrosis, a higher dose and/or different dosing interval compared with those used in this study may be necessary.

Full text

PDF
1414

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arguedas A. G., Stutman H. R., Zaleska M., Knupp C. A., Marks M. I., Nussbaum E. Cefepime. Pharmacokinetics and clinical response in patients with cystic fibrosis. Am J Dis Child. 1992 Jul;146(7):797–802. doi: 10.1001/archpedi.1992.02160190029013. [DOI] [PubMed] [Google Scholar]
  2. Arvidsson A., Alván G., Strandvik B. Difference in renal handling of cefsulodin between patients with cystic fibrosis and normal subjects. Acta Paediatr Scand. 1983 Mar;72(2):293–294. doi: 10.1111/j.1651-2227.1983.tb09715.x. [DOI] [PubMed] [Google Scholar]
  3. Barbhaiya R. H., Forgue S. T., Shyu W. C., Papp E. A., Pittman K. A. High-pressure liquid chromatographic analysis of BMY-28142 in plasma and urine. Antimicrob Agents Chemother. 1987 Jan;31(1):55–59. doi: 10.1128/aac.31.1.55. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bosso J. A., Saxon B. A., Matsen J. M. Comparative activity of cefepime, alone and in combination, against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients. Antimicrob Agents Chemother. 1991 Apr;35(4):783–784. doi: 10.1128/aac.35.4.783. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Drusano G. L. Role of pharmacokinetics in the outcome of infections. Antimicrob Agents Chemother. 1988 Mar;32(3):289–297. doi: 10.1128/aac.32.3.289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fuchs P. C., Jones R. N., Barry A. L., Thornsberry C. Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1985 May;27(5):679–682. doi: 10.1128/aac.27.5.679. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hedman A., Adan-Abdi Y., Alvan G., Strandvik B., Arvidsson A. Influence of the glomerular filtration rate on renal clearance of ceftazidime in cystic fibrosis. Clin Pharmacokinet. 1988 Jul;15(1):57–65. doi: 10.2165/00003088-198815010-00005. [DOI] [PubMed] [Google Scholar]
  8. Leeder J. S., Spino M., Isles A. F., Tesoro A. M., Gold R., MacLeod S. M. Ceftazidime disposition in acute and stable cystic fibrosis. Clin Pharmacol Ther. 1984 Sep;36(3):355–362. doi: 10.1038/clpt.1984.187. [DOI] [PubMed] [Google Scholar]
  9. Spino M. Pharmacokinetics of drugs in cystic fibrosis. Clin Rev Allergy. 1991 Spring-Summer;9(1-2):169–210. doi: 10.1007/978-1-4612-0475-6_11. [DOI] [PubMed] [Google Scholar]
  10. Vogelman B., Gudmundsson S., Leggett J., Turnidge J., Ebert S., Craig W. A. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis. 1988 Oct;158(4):831–847. doi: 10.1093/infdis/158.4.831. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES